Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer.

Katherine B Winfree Kristin M Sheffield Zhanglin Lin CuiTomoko SugiharaJosephine Feliciano

Published in: Current medical research and opinion (2021)

The majority of patients treated with first-/second-generation EGFR TKIs went on to receive osimertinib in the 2L setting, but overall, only a third of patients had received molecular testing at progression. Improved testing frequency is vital to inform treatment decisions.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
ejection fraction
newly diagnosed
chronic kidney disease
type diabetes
metabolic syndrome
advanced non small cell lung cancer
combination therapy
weight loss
insulin resistance
single molecule
smoking cessation